List of Lumason drug patents

Lumason is owned by Bracco.

Lumason contains Sulfur Hexafluoride Lipid-Type A Microspheres.

Lumason has a total of 2 drug patents out of which 0 drug patents have expired.

Lumason was authorised for market use on 15 October, 2014.

Lumason is available in for suspension;intravenous dosage forms.

The generics of Lumason are possible to be released after 06 July, 2038.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10335502 BRACCO Freeze-dried formulation for gas-filled microvesicles
Jul, 2038

(15 years from now)

US10232061 BRACCO Freeze-dried formulation for gas-filled microvesicles
Jul, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Nov 13, 2022

Drugs and Companies using SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES ingredient

Market Authorisation Date: 15 October, 2014

Treatment: NA

Dosage: FOR SUSPENSION;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic